The Impacts and Changes Related to the Cancer Drug Resistance Mechanism

Abstract

Background: Cancer drug resistance remains a difficult barrier to effective treatment, necessitating a thorough understanding of its multi-layered mechanism. Objective: This study aims to comprehensively explore the diverse mechanisms of cancer drug resistance, assess the evolution of resistance detection methods, and identify strategies for overcoming this challenge. The evolution of resistance detection methods and identification strategies for overcoming the challenge. Methods: A comprehensive literature review was conducted to analyze intrinsic and acquired drug resistance mechanisms, including altered drug efflux, reduced uptake, inactivation, target mutations, signaling pathway changes, apoptotic defects, and cellular plasticity. The evolution of mutation detection techniques, encompassing clinical predictions, experimental approaches, and computational methods, was investigated. Strategies to enhance drug efficacy, modify pharmacokinetics, optimizoptimizee binding modes, and explore alternate protein folding states were examined. Results: The study comprehensively overviews the intricate mechanisms contributing to cancer drug resistance. It outlines the progression of mutation detection methods and underscores the importance of interdisciplinary approaches. Strategies to overcome drug resistance challenges, such as modulating ATP-binding cassette transporters and developing multidrug resistance inhibitors, are discussed. The study underscores the critical need for continued research to enhance cancer treatment efficacy. Conclusion: This study provides valuable insights into the complexity of cancer drug resistance mechanisms, highlights evolving detection methods, and offers potential strategies to enhance treatment outcomes.

The role of HOTAIR in the modulation of resistance to anticancer therapy

“…The major anticancer therapies include surgery, radiotherapy, endocrine therapy, chemotherapy, molecular targeted therapy, and immunotherapy, used as monotherapy and in combination with each other ( Pérez-Herrero and Fernández-Medarde, 2015 ; Kruger et al, 2019 ; Bedard et al, 2020 ; Kareliotis et al, 2020 ; Jin, Wang and Bernards, 2023 ). However, anticancer drug resistance represents a major clinical challenge and one of the main causes of poor prognosis, tumour metastasis and recurrence ( Kalbasi and Ribas, 2020 ; Varshney et al, 2023 ). Therapeutic resistance is a complex process that can arise from genetic, epigenetic, and microenvironmental factors.…”